Agenus Inc. Return on Tangible Assets

Return on Tangible Assets of AGEN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Return on Tangible Assets growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Return on Tangible Assets for 2019 was 1154.01% (a -329.95% decrease from previous year)
  • Annual Return on Tangible Assets for 2018 was -501.85% (a 79.71% increase from previous year)
  • Annual Return on Tangible Assets for 2017 was -279.25% (a 67.06% increase from previous year)
  • Twelve month Return on Tangible Assets ending June 29, 2020 was 1866.91% (a -139.76% decrease compared to previous quarter)
  • Twelve month trailing Return on Tangible Assets decreased by -89.1% year-over-year
Trailing Return on Tangible Assets for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
1866.91% -4695.17% 1154.01% 17130.15%
Visit stockrow.com/AGEN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Return on Tangible Assets of Agenus Inc.

Most recent Return on Tangible Assetsof AGEN including historical data for past 10 years.

Interactive Chart of Return on Tangible Assets of Agenus Inc.

Agenus Inc. Return on Tangible Assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 1154.01%
2018 -501.85%
2017 -279.25%
2016 -167.16%
2015 -51.67%
2014 -108.25%
2013 -160.83%
2012 -59.37%
2011 -211.35%
2010 -104.92%
2009 -88.7%

Business Profile of Agenus Inc.

Sector: Medical
Industry: Drugs
Agenus Inc., a clinical-stage immuno-oncology company, engages in advancing a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Further, it develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bifunctional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. Additionally, the company engages in the development INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390 – an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.